

RECEIVED

MAR 26 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

MORRISON & FOERSTER

SAN DIEGO

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/771,312	01/26/2001	1642	1489	511582000100	14	48	16

CONFIRMATION NO. 7650

UPDATED FILING RECEIPT



OC000000012166851

36327

 AGENSYS C/O MORRISON & FOERSTER LLP
 3811 VALLEY CENTRE DRIVE, SUITE 500
 SAN DIEGO, CA 92130

Date Mailed: 03/23/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 Aya Jakobovits, Beverly Hills, CA;
 Daniel E.H. Afar, Brisbane, CA;
 Pia M. Challita-Eid, Encino, CA;
 Elana Levin, Los Angeles, CA;
 Steve Chappell Mitchell, Santa Monica, CA;
 Rene S. Hubert, Los Angeles, CA;

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/178,560 01/26/2000

Foreign Applications

If Required, Foreign Filing License Granted: 01/04/2002

Projected Publication Date: 07/01/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

84P2A9: a prostate and testis specific protein highly expressed in prostate cancer
protein

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



RECEIVED

DEC 20 2002

TECH CENTER 1600/2900

5

#15

✓

**84P2A9: A PROSTATE AND TESTIS SPECIFIC PROTEIN HIGHLY
EXPRESSED IN PROSTATE CANCER**

This application claims the benefit of United States provisional patent application number 60/178,560, filed January 26, 2000, the entire contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

The invention described herein relates to a novel gene and its encoded protein, termed 84P2A9, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 84P2A9, particularly prostate cancers.

BACKGROUND OF THE INVENTION

- 10 Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from cancer every year. In the United States alone, cancer causes the death of well over a half-million people annually, with some 1.4 million new cases diagnosed per year. While deaths from heart disease have been declining significantly, those resulting from cancer generally are on the rise. In the early part of the
- 15 next century, cancer is predicted to become the leading cause of death.

- Worldwide, several cancers stand out as the leading killers. In particular, carcinomas of the lung, prostate, breast, colon, pancreas, and ovary represent the primary causes of cancer death. These and virtually all other carcinomas share a common lethal feature. With very few exceptions, metastatic disease from a carcinoma is fatal.
- 20 Moreover, even for those cancer patients who initially survive their primary cancers, common experience has shown that their lives are dramatically altered. Many cancer patients experience strong anxieties driven by the awareness of the potential for recurrence or treatment failure. Many cancer patients experience physical debilitations following treatment. Furthermore, many cancer patients experience a recurrence.

- 25 Worldwide, prostate cancer is the fourth most prevalent cancer in men. In North America and Northern Europe, it is by far the most common cancer in males and is the second leading cause of cancer death in men. In the United States alone, well over 40,000 men die annually of this disease - second only to lung cancer. Despite the



GATES & COOPER LLP
United States Patent Application
COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

84P2A9: A PROSTATE AND TESTIS SPECIFIC PROTEIN HIGHLY EXPRESSED IN PROSTATE CANCER

The specification of which:

- a. ☐ is attached hereto
- b. ☒ was filed on January 26, 2001 as United States Application Number or PCT International Application Number 09/771,312 and was amended on (if applicable), which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (attached hereto).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT application having a filing date before that of the application on the basis of which priority is claimed:

- a. ☒ no such applications have been filed.
- b. ☐ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
OTHER FOREIGN APPLICATION(S), IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or 365(c) of any PCT international application(s) designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

-2-

U.S. PARENT APPLICATION OR PCT PARENT NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

I hereby claim the benefit under Title 35, United States Code § 119(c) of any United States provisional application(s) listed below:

U.S. PROVISIONAL APPLICATION NUMBER	DATE OF FILING (Day, Month, Year)
60/178,560	26 JAN 01

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

George H. Gates	Registration No. 33,500
Victor G. Cooper	Registration No. 39,641
Karen S. Canady	Registration No. 39,927
William J. Wood	Registration No. 42,236
Jason S. Feldmar	Registration No. 39,187
Bradley K. Lortz	Registration No. 45,472


I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Gates & Cooper LLP to the contrary.

Please direct all correspondence in this case to the firm of Gates & Cooper LLP at the address indicated below:

GATES & COOPER LLP
Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, CA 90045

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1)	Full Name Of Inventor	Family Name Jakobovits	First Given Name Aya	Second Given Name
	Residence & Citizenship	City Beverly Hills	State or Foreign Country California	Country of Citizenship USA
	Post Office Address	Post Office Address 3135 Hutton Drive	City Beverly Hills	State & Zip Code/Country California 90210/USA
Signature of Inventor(1): <i>Aya Jakobovits</i>				Date: 3/9/01

(2)	Full Name Of Inventor	Family Name Afar	First Given Name Daniel	Second Given Name E.H.
	Residence & Citizenship	City Brisbane	State or Foreign Country California	Country of Citizenship Canada
	Post Office Address	Post Office Address 435 Visitation Avenue	City Brisbane	State & Zip Code/Country California 94005/USA
Signature of Inventor(2): 				Date: May 23, 2009
(3)	Full Name Of Inventor	Family Name Challita-Eid	First Given Name Pia	Second Given Name M.
	Residence & Citizenship	City Encino	State or Foreign Country California	Country of Citizenship Lebanon
	Post Office Address	Post Office Address 15745 Morrison Street	City Encino	State & Zip Code/Country California 91436/USA
Signature of Inventor(3):				Date:
(4)	Full Name Of Inventor	Family Name Levin	First Given Name Elana	Second Given Name
	Residence & Citizenship	City Los Angeles	State or Foreign Country California	Country of Citizenship USA
	Post Office Address	Post Office Address 10874 Rose Avenue, #9	City Los Angeles	State & Zip Code/Country California 90034/USA
Signature of Inventor(4):				Date:
(5)	Full Name Of Inventor	Family Name Mitchell	First Given Name Steve	Second Given Name Chappell
	Residence & Citizenship	City Santa Monica	State or Foreign Country California	Country of Citizenship USA
	Post Office Address	Post Office Address 2417-1/2 4th Street	City Santa Monica	State & Zip Code/Country California 90405/USA
Signature of Inventor(5):				Date:
(6)	Full Name Of Inventor	Family Name Hubert	First Given Name Rene	Second Given Name S.
	Residence & Citizenship	City Los Angeles	State or Foreign Country California	Country of Citizenship Canada
	Post Office Address	Post Office Address 1644 North Occidental Blvd.	City Los Angeles	State & Zip Code/Country California 90026/USA
Signature of Inventor(6):				Date:

(2)	Full Name Of Inventor	Family Name Afar	First Given Name Daniel	Second Given Name E.H.
	Residence & Citizenship	City Brisbane	State or Foreign Country California	Country of Citizenship Canada
	Post Office Address	Post Office Address 435 Visitation Avenue	City Brisbane	State & Zip Code/Country California 94005/USA
Signature of Inventor(2):				Date:
(3)	Full Name Of Inventor	Family Name Challita-Ead	First Given Name Pia	Second Given Name M.
	Residence & Citizenship	City Encino	State or Foreign Country California	Country of Citizenship Lebanon
	Post Office Address	Post Office Address 15745 Morrison Street	City Encino	State & Zip Code/Country California 91436/USA
Signature of Inventor(3): <i>Pia Challita-Ead</i>				Date: 3/12/01
(4)	Full Name Of Inventor	Family Name Levin	First Given Name Elana	Second Given Name
	Residence & Citizenship	City Los Angeles	State or Foreign Country California	Country of Citizenship USA
	Post Office Address	Post Office Address 10874 Rose Avenue, #9	City Los Angeles	State & Zip Code/Country California 90034/USA
Signature of Inventor(4): <i>Elana Levin</i>				Date: 3/12/01
(5)	Full Name Of Inventor	Family Name Mitchell	First Given Name Steve	Second Given Name Chappell
	Residence & Citizenship	City Santa Monica	State or Foreign Country California	Country of Citizenship USA
	Post Office Address	Post Office Address 2417-1/2 4th Street	City Santa Monica	State & Zip Code/Country California 90405/USA
Signature of Inventor(5): <i>Steve Mitchell</i>				Date: 3/12/00
(6)	Full Name Of Inventor	Family Name Hubert	First Given Name Rene	Second Given Name S.
	Residence & Citizenship	City Los Angeles	State or Foreign Country California	Country of Citizenship Canada
	Post Office Address	Post Office Address 1644 North Occidental Blvd.	City Los Angeles	State & Zip Code/Country California 90026/USA
Signature of Inventor(6): <i>Rene Hubert</i>				Date: 3-14-01

§ 1.56 Duty to disclose information material to patentability.

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
- (2) it refutes, or is inconsistent with, a position the applicant takes in:
 - (i) opposing an argument of unpatentability relied on by the Office, or
 - (ii) asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) each inventor named in the application;
- (2) each attorney or agent who prepares or prosecutes the application; and
- (3) every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.